Clinical Trials Logo

Lung Diseases clinical trials

View clinical trials related to Lung Diseases.

Filter by:

NCT ID: NCT05505409 Recruiting - Clinical trials for Interstitial Lung Disease

Efficacy and Safety of Pirfenidone in CTD-ILD

Start date: June 22, 2022
Phase: Phase 4
Study type: Interventional

A single-center randomized controlled study will be used to observe the efficacy and safety of pirfenidone on CTD-ILD patients for 24 months. The main research endpoints is the lung function (FVC) at 6 months. The clinical dyspnea score, 6-minute walking distance, index of lung function and imaging indicators are evaluated, as well as primary disease activity and adverse reactions of therapy with glucocorticoid and immunosuppressants up to 24 months.

NCT ID: NCT05504993 Completed - Clinical trials for Comorbidities and Coexisting Conditions

Are Comorbidities Related to Frequent Severe Exacerbations of AECOPD

Start date: January 1, 2018
Phase:
Study type: Observational

INTRODUCTION: Relationship between comorbidities and COPD is two-sided. While the number of comorbidities increasing, the frequency of acute exacerbations of COPD (AECOPD) is increasing, too. Comorbidity indexes can be used for recognition of comorbidities while managing COPD patients. In the present study, it is aimed to compare comorbidity indexes such as Charlson Comorbidity Index, COMCOLD and COTE in the matter of exacerbation frequency. METHOD: Subjects hospitalized for AECOPD, admitted to the study. Exacerbation severity, frequency, further exacerbations for a 1-year period in the follow-up period and CCI, COMCOLD and COTE scores were recorded. High and low comorbidity groups were compared for AECOPD frequency, severity, and further exacerbations.

NCT ID: NCT05503030 Recruiting - Clinical trials for Lung Diseases, Interstitial

Correlation Between Changes in Lung Function and Changes in Cough and Dyspnoea in Nintedanib-treated Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) Patients

Start date: November 1, 2022
Phase:
Study type: Observational

The aim of this study is to identify correlations between change from the baseline at Month 24 in Forced Vital Capacity (FVC) (% predicted and mL) and change from the baseline at Month 24 in cough or dyspnoea scores [points] as measured in the living with pulmonary fibrosis questionnaire (L-PF) over 24 months of nintedanib treatment in patients with connective tissues disease-associated progressive fibrosing interstitial lung disease (CTD associated PF-ILD) under routine clinical practice conditions in Greece.

NCT ID: NCT05496374 Recruiting - Clinical trials for Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD)

A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of SPR720 as Compared With Placebo for the Treatment of Participants With Mycobacterium Avium Complex (MAC) Pulmonary Disease

Start date: December 14, 2022
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate 1. The microbiological response and clinical efficacy of SPR720 compared with placebo in participants with nontuberculous mycobacteria pulmonary disease (NTM-PD). 2. The safety and tolerability of SPR720 in a participants population with NTM- PD 3. The pharmacokinetic (PK) of SPR719, active moiety, following orally (po) administered prodrug SPR720 in a participant population with NTM-PD.

NCT ID: NCT05495256 Completed - Asthma Clinical Trials

Monitoring Metered Dose Inhalation (MDI) Volume and Timing With a Respimetrix Device in Obstructive Lung Disease.

Start date: May 1, 2021
Phase: N/A
Study type: Interventional

To Determine whether use of the Respimetrix flow test device a) can determine "good" versus "poor" inhaler techniques, and b) the effects of the inhaler training on technique.

NCT ID: NCT05494957 Not yet recruiting - Clinical trials for Nontuberculous Mycobacterial Lung Disease

Clinical Study of New Intensive Treatment Regimen for Severe Nontuberculous Mycobacterial Pulmonary Disease

NTM-PD
Start date: August 5, 2022
Phase: Phase 4
Study type: Interventional

Investigators have selected a number of new drugs, including bedaquiline, to form a regimen to conduct clinical studies for the treatment of severe NTM lung disease.

NCT ID: NCT05492994 Recruiting - Clinical trials for Lung Diseases, Interstitial

A Study to Test Different Imaging Techniques in Patients With Different Types of Interstitial Lung Disease

Start date: December 16, 2022
Phase: N/A
Study type: Interventional

The main objectives of this imaging biomarker study are to assess the annual lung function change in patients with progressive fibrosing interstitial lung disease (PF-ILD) including idiopathic pulmonary fibrosis (IPF), with Usual Interstitial Pneumonia (UIP) or probable UIP Computer Tomography (CT) pattern, and to monitor lung structural changes.

NCT ID: NCT05492877 Active, not recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease (COPD)

An Efficacy and Safety Study of Mitiperstat (AZD4831) (MPO Inhibitor) vs Placebo in the Treatment of Moderate to Severe COPD.

CRESCENDO
Start date: November 14, 2022
Phase: Phase 2
Study type: Interventional

This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.

NCT ID: NCT05492448 Recruiting - Type 2 Diabetes Clinical Trials

Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease

Start date: September 19, 2022
Phase: N/A
Study type: Interventional

This trial is a randomized, double-blind, parallel placebo clinical trial, the purpose of which is to investigate whether the adjuvant therapy of using probiotics during the treatment of diabetic patients can decrease blood sugar levels significantly in comparison with placebo, and observe if the reduced lung function could be recovered in patients with type 2 diabetes (T2DM) and chronic obstructive pulmonary disease (COPD) simultaneously.

NCT ID: NCT05482607 Recruiting - Systemic Sclerosis Clinical Trials

Evaluation of HRCT Patterns in Systemic Sclerosis-associated Interstitial Lung Disease

LUNGSCLEROCT
Start date: January 1, 2023
Phase:
Study type: Observational

Systemic sclerosis (SSc) is a heterogeneous systemic autoimmune disease with distinct prognosis according to patients. Interstitial lung disease (ILD) concerns almost 50 % of SSc patients and represents the main cause of mortality. SSc-ILD is variable: from limited forms (with asymptomatic patients) to extensive lesions. Disease course in SSc-ILD is also highly variable: patients can experience stable disease, slow or fast progression. Investigators performed unsupervised clustering analysis to classify SSc-ILD according to elementary radiological lesions on HRCT scan.